Immune Checkpoint Inhibitors
BioAtla®’s CAB immune Checkpoint inhibitors and stimulators (CAB-C’s) are engineered to target either immune cells or tumor cells. CAB-C’s are active in selected microenvironments within the body and prevent tumor cells from inhibiting immune cells, thereby enabling the body’s immune cells to remain activated. These activated immune cells can shrink the tumor, individually or in combination with other drugs, and may eradicate the cancer.

Representative Cancer Indications
Non small cell lung cancer (NSCLC), Melanoma

Cytotoxic T Lymphocyte Associated Protein-4 (CTLA-4) is a receptor on the surface of helper T cells that binds CD80 and CD86 on antigen presenting cells, transmitting an inhibitory signal to T cells. By reversing this inhibition anti-CTLA-4 antibodies have been shown to have great benefit in treating cancer, but can also cause toxicity by activating T cells generally, especially in combination with other immune checkpoint antibodies. BioAtla’s CAB-CTLA4 antibody helps target this activation to the tumor microenvironment, reducing on-target toxicity and enabling more powerful and safer combination therapies.